Immunovant, Inc. (IMVT) - Latest Market Data

Price & Market Data

Price: $28.65

Daily Change: -$0.41 / 1.43%

Daily Range: $27.93 - $29.44

Market Cap: $5,831,196,672

Daily Volume: 1,004,581

Performance Metrics

1 Week: 2.91%

1 Month: 14.05%

3 Months: 7.38%

6 Months: 22.70%

1 Year: 96.91%

YTD: 12.71%

About Immunovant, Inc. (IMVT)

Get up-to-date information on Immunovant, Inc. (IMVT). The stock is trading at 28.65, with a daily performance indicating a change of -$0.41 / 1.43%. Its market cap is recorded at 5,831,196,672. Delve into detailed performance metrics, from short-term (1-week) to long-term (1-year) and year-to-date returns.

Company Details

Employees: 362

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Selected stocks

Churchill Downs, Incorporated (CHDN)

Medallion Financial Corp. (MFIN)

Kelly Services, Inc. (KELYA)

GoHealth, Inc. (GOCO)